ArticlePolymers2025
Preparation of Polymerized High Internal Phase Emulsion Membranes with High Open-Cellular Extent and High Toughness via RAFT Polymerization.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Porous polymer membranes with highly interconnected open-cellular structure and high toughness are crucial for various application fields. Polymerized high internal phase emulsions (polyHIPEs), which usually exist as monoliths, possess the advantages of high porosity and good connectivity. However, it is difficult to prepare membranes due to brittleness and easy pulverization. Copolymerizing acrylate soft monomers can effectively improve the toughness of polyHIPEs, but it is easy to cause emulsion instability and pore collapse. In this paper, stable HIPEs with a high content of butyl acrylate (41.7 mol% to 75 mol% based on monomers) can be obtained by using a composite emulsifier (30 wt.% based on monomers) consisting of Span80/DDBSS (9/2 in molar ratio) and adding 0.12 mol·L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.